Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs GSK 2636771 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 14 Feb 2018 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.